Suchergebnisse

PubPharm (31)

1

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy : the ARON-2 study

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Massari, F. | Santoni, M. | Takeshita, H. | +94

2

Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2023

von Smoot, K. | Marginean, H. | Gervasi-Follmar, T. | +3

3

Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children : A Case Series and Literature Review

enthalten in: Ophthalmic surgery, lasers & imaging retina | 2023

von Jung, E. | Lee, T. | Nagiel, A.

4

The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age

enthalten in: Clinical and experimental rheumatology | 2022

von Specker, C. | Aringer, M. | Burmester, G. | +6

5

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma : a subgroup analysis from the LOTIS-2 study

enthalten in: Blood advances | 2022

von Alderuccio, J. | Ai, W. | Radford, J. | +14

6

Tocilizumab for the Critically Ill With Severe COVID-19 : A Community Hospital Case Series

enthalten in: Journal of pharmacy practice | 2022

von McKenzie, M. | Lee, Y. | Mathew, J. | +4

7

Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum

enthalten in: The British journal of dermatology | 2022

von Navrazhina, K. | Frew, J. | Grand, D. | +5

CommentIn: Br J Dermatol. 2022 Aug;187(2):138-139. - PMID 35531874

8

Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia : Results from the HOPE study

enthalten in: The Australasian journal of dermatology | 2022

von Foley, P. | Spelman, L. | Murrell, D. | +3

9

Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours : Results from the KEYNOTE-158 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Maio, M. | Amonkar, M. | Norquist, J. | +15

10

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

enthalten in: American journal of clinical dermatology | 2022

von Beck, L. | Deleuran, M. | Bissonnette, R. | +11